Antitumor activity liposome-encapsulated doxorubicin advanced breast cancer phase II study Previous studies animals liposome-encapsulated doxorubicin LED cardiac toxicity free doxorubicin antitumor activity phase study LED maximum dose dose-limiting toxicity granulocytopenia LED patients advanced measurable breast cancer LED doses weeks intravenous infusion Regression disease patients patients complete regression index lesion mean duration responses months Hematologic toxicity grade leukopenia patients Gastrointestinal toxicity mucositis mild tolerable Alopecia patients complete Twelve patients cumulative doses LED radionuclide ventriculograms patients cumulative dose endomyocardial biopsies biopsy results Billingham cumulative LED dose changes mild myofibrillar loss dilatation sarcoplasmic reticulum cardiac myocytes patients decreases left ventricular ejection fraction patients total dose LED decline left ventricular ejection fraction clinical evidence congestive heart failure Billingham grade endomyocardial biopsy 